Clinical Trials on High-risk Patients in New Zealand

Total 633 results

Abiomed Inc.

Completed

PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI (PROTECT I)

Patients Undergoing High Risk PCI.

United States, Netherlands
University Hospital of Cologne
Karolinska Institutet; University Hospital of North Norway; Goethe University; McGill... and other collaborators

Unknown

Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens (PILGRIM)

Patients at High Risk of Antibacterial Treatment Upon Admission

Germany
New York City Health and Hospitals Corporation
New York State Department of Health

Completed

A Patient Centered Intervention to Improve Health and Reduce Medicaid Costs

High-risk, High-cost Medicaid Services Users

United States
Magenta Medical Ltd.

Recruiting

Magenta Elevate™ EFS in High-Risk PCI Patients

High-risk Percutaneous Coronary Intervention

United States
Memorial Sloan Kettering Cancer Center

Completed

Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

High Risk for Postoperative Cardiovascular Events

United States
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine; The Cleveland Clinic; Vanderbilt University...

Active, not recruiting

Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery

Thoracic Surgery | Atrial Fibrillation in High Risk Patients

United States
Abiomed Inc.

Enrolling by invitation

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

High-Risk Percutaneous Coronary Intervention

United States
ExCellThera inc.
Memorial Sloan Kettering Cancer Center

Recruiting

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Cord Blood Transplant | High Risk Myeloid Malignancies

United States
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Queens College, The City University of New York
State University of New York at Buffalo

Terminated

Enhancing Father's Ability to Support Their Preschool Child

Parenting | Prevention | Child Maltreatment | Fathers | High-risk

United States
Memorial Sloan Kettering Cancer Center

Completed

A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing

Cancer Survivors | Statin Use Among High Risk Survivors

United States
Australian and New Zealand Intensive Care Research...

Completed

Nutrition Therapy in Adult Patients Requiring ECMO in Australia and New Zealand

Patients on Extracorporeal Membrane Oxygenation

Australia, New Zealand
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Adelphi University; Queen's Hospital Center

Completed

Measurement of Cancer-Related Risk Perception in Smokers

Survey | Risk Perception | Cancer Related-Risks | Focus Group

United States
University Hospital, Basel, Switzerland

Completed

Validation Study of ClassIntra® (ClassIntra®)

Postoperative Complications | Intraoperative Complications | Patient Safety | Risk Management

New Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
Memorial Sloan Kettering Cancer Center
Tel-Aviv Sourasky Medical Center; Sheba Medical Center; Princess Alexandra Hospital...

Active, not recruiting

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

High-Risk Nevus Phenotype

United States
Northwell Health

Terminated

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

High Risk MC4R Genotype | Low Risk MC4R Genotype | One Week or Less Antipsychotic Lifetime Exposure

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)

Completed

Glutamate Reducing Interventions in Schizophrenia

Clinical High Risk for Psychosis

United States
University of Otago
Australian and New Zealand College of Anaesthetists

Completed

Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief

Adult Patients Scheduled for 3rd Molar Teeth Extractions

New Zealand
New York State Psychiatric Institute

Terminated

Gabapentin in Patients at Clinical Risk for Psychosis

Clinical High Risk for Psychosis

United States
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH)

Recruiting

Telehealth Cognitive Behavioral Therapy for Youth at Risk for Psychosis

Clinical High Risk for Psychosis (CHR)

United States
Bioventus LLC

Enrolling by invitation

Observational, Non-interventional Use of LIPUS to Mitigate Fracture Non-union in Patients at Risk (BONES)

Mitigation of Fracture Non-union in Patients at Risk

United States
Arthrosi Therapeutics

Completed

Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

Gout Patients

New Zealand
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer

High Risk for Developing Breast Cancer

United States
National Cancer Institute (NCI)
Cancer and Leukemia Group B

Completed

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Breast Cancer | High Risk | Cyclophosphamide | Positive Nodes | Doxorubicin

United States
Edwards Lifesciences

Terminated

Hypotension Prediction Index (HPI) SMART-BP Trial

Moderate to High-risk Noncardiac Surgery

United States
University of New Mexico
National Institute of Mental Health (NIMH)

Completed

Feasibility of an Early Detection Program for Early Psychosis on a College Campus

Psychosis | Clinical High Risk for Psychosis | First Episode Psychosis

United States
Yale University

Terminated

Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

Clinical High Risk for Psychosis

United States
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH)

Recruiting

Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication (EaSIE)

First Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)

United States
Atara Biotherapeutics
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Completed

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

United States
VA Eastern Colorado Health Care System
University of Pennsylvania; Columbia University; United States Department of... and other collaborators

Completed

A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans- Study 1 (SAFE VET)

Suicide Risk | Patient

United States
Yale University

Completed

PRIME vs Usual Care for Clinical High Risk

Clinical High Risk Syndrome for Psychosis

United States
Institute of Liver and Biliary Sciences, India

Not yet recruiting

Spleen Stiffness as a Measure to Assess the REsponse to β Blocker Therapy (SPARE-B)

High Risk Esophageal Varices

India
Schrödinger, Inc.

Recruiting

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic Syndromes

United States
Memorial Sloan Kettering Cancer Center

Completed

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Bladder Cancer | High Risk Superficial

United States
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy
Trigemina, Inc

Completed

TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine

High Frequency Episodic Migraine and Chronic Migraine

Chile, New Zealand, Australia
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy, United Kingdom, France
Brigham and Women's Hospital
National Institute of Mental Health (NIMH); Yale University; Orygen

Recruiting

AMP SCZ® Observational Study: PREDICT-DPACC (AMP SCZ)

Psychosis | Remission | Conversion | Clinical High Risk

United States, United Kingdom, Canada, Italy, Australia, Chile, China, Denmark, Germany, Hong Kong, Korea, Republic of, Singapore, Spain, Switzerland
PDS Biotechnology Corp.

Completed

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

High-risk HPV Infection and Biopsy-proven CIN1

United States
Novartis Pharmaceuticals

Terminated

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

High Risk MDS

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Recruiting

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Breast Cancer | Early-stage Breast Cancer | High Risk Breast Carcinoma

United States
Jazz Pharmaceuticals
The Leukemia and Lymphoma Society

Completed

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

High Risk Acute Myeloid Leukemia

United States, Canada
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | High-Risk

United States
Heinrich-Heine University, Duesseldorf
Abiomed Inc.; Profil Clinical Trials Coordination GmbH

Recruiting

Protect Kidney Trial

High-risk Percutaneous Coronary Intervention | Induced Acute Kidney Injury

Germany
Atara Biotherapeutics
Memorial Sloan Kettering Cancer Center

Completed

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma

United States
Memorial Sloan Kettering Cancer Center

No longer available

Naxitamab and GM-CSF in People With Neuroblastoma

High-Risk Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Neuroblastoma | High-risk Neuroblastoma | Metastatic Neuroblastoma

United States
Yale University

Completed

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

High Risk Atherosclerotic Cardiovascular Disease

United States
Far Eastern Memorial Hospital

Completed

Predictors of Recurrence for High Risk Endometrial Cancer Patients

High-risk Endometrial Cancer

Taiwan

Clinical Trials on High-risk Patients in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations